VLA2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry
1998

VLA2 Integrin Expression in Breast Carcinomas

Sample size: 204 publication Evidence: moderate

Author Information

Author(s): C Charpin, S Garcia, D Bergeret, L Andrac, N Horschowski, R Choux, MN Lavaut

Primary Institution: Department of Pathology, Faculte de Medecine Timone; Department of Pathology, Hôpital Nord, Marseille, France

Hypothesis

The study investigates the role of VLA2 integrin in the metastatic process of breast carcinomas.

Conclusion

VLA2 expression in breast carcinomas is independent of most histoprognostic indicators and requires further investigation to determine its clinical relevance.

Supporting Evidence

  • VLA2 was positive in 23.5% of the tumors studied.
  • VLA2 expression was independent of tumor size, grade, type, and aneuploidy.
  • VLA2 significantly correlated with ELAM, VCAM, VLA3, and P-glycoprotein.

Takeaway

This study looked at a protein called VLA2 in breast cancer to see if it helps cancer spread. They found that VLA2 levels didn't really change with other important cancer signs.

Methodology

The study used automated and quantitative immunohistochemistry to evaluate VLA2 expression in frozen tissue sections from breast carcinoma patients.

Potential Biases

Methodological bias may arise from tissue fixation and variations in immunohistochemical methods.

Limitations

The exact role of VLA2 in tumor cell dissemination remains unclear, and the clinical relevance of VLA2 immunodetection requires further investigation.

Participant Demographics

Mean age of participants was 56.4 years, with a range from 32 to 83 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication